help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fisac, C.
Right arrow Articles by Podzamczer, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fisac, C.
Right arrow Articles by Podzamczer, D.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*AIDS Medicines
The Journal of Clinical Endocrinology & Metabolism Vol. 88, No. 11 5186-5192
Copyright © 2003 by The Endocrine Society

A Comparison of the Effects of Nevirapine and Nelfinavir on Metabolism and Body Habitus in Antiretroviral-Naive Human Immunodeficiency Virus-Infected Patients: A Randomized Controlled Study

Cesar Fisac, Nuria Virgili, Elena Ferrer, Maria J. Barbera, Emilio Fumero, Concepcio Vilarasau and Daniel Podzamczer

Endocrinology (C.F., N.V., C.V.) and Infectious Disease (E.F., M.J.B., E.F., D.P.) Services, Hospital Universitario de Bellvitge, 08907 L’Hospitalet de Llobregat, Barcelona, Spain

Address all correspondence and requests for reprints to: Cesar Fisac, R.D., Endocrinology and Nutrition Service, Hospital Universitario de Bellvitge, c/Feixa Llarga s/n, 08907 L’Hospitalet de Llobregat, Barcelona, Spain. E-mail: cfisac{at}csub.scs.es.

New HIV therapies have significantly increased survival, but are associated with multiple metabolic changes, most of them related to the protease inhibitors (PIs). The objective of this study was to elucidate and compare morphological and metabolic alterations in HIV-infected antiretroviral-naive patients receiving two nucleosides plus the PI nelfinavir (NFV) or the nonnucleoside reverse transcriptase inhibitor nevirapine (NVP). Forty-three patients (NFV, n = 20; NVP, n = 23) receiving 6–12 months of treatment were analyzed. Morphological changes were evaluated by bioelectrical impedance analysis, standard anthropometrics, and clinical examination. Serum total cholesterol (TC), low-density and high- density (HDL-c) lipoprotein cholesterol, triglycerides, glucose, and insulin were determined, among other metabolic parameters. No baseline differences were observed between groups. TC increased in both arms (NVP, 11%; NFV, 17%). HDL-c also increased in both groups, although more markedly in those receiving NVP (44% vs. 20%); on-treatment levels were also elevated (1.57 vs. 1.28 mmol/liter). As a consequence of these changes, the TC/HDL-c ratio dropped by 22% in the NVP arm and remained stable in the NFV group. With the use of NFV, the TC/HDL-c ratio and attendant cardiovascular risk did not change. In contrast, NVP offered benefits regarding lipid status, as manifested by enhanced HDL-c concentrations and decreased TC/HDL-c ratios. Inclusion of NVP should be considered when deciding upon antiretroviral regimens for patients at high coronary risk.

This work was supported in part by Glaxo, Roche, and Boehringer Ingelheim, Spain, by the Fundació August Pi i Sunyer, Spain, and by the Red Tematica Cooperativa de Investigacion en SIDA (Red de grupos 173) del FISss, Spain. It was presented in part at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 2000.

Abbreviations: apo, Apolipoprotein; BMI, body mass index; CVD, cardiovascular disease; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; NFV, nelfinavir; NVP, nevirapine; PI, protease inhibitor; TC, total cholesterol; TG, triglycerides.




This article has been cited by other articles:


Home page
CirculationHome page
C. Grunfeld, D. P. Kotler, D. K. Arnett, J. M. Falutz, S. M. Haffner, P. Hruz, H. Masur, J. B. Meigs, K. Mulligan, P. Reiss, et al.
Contribution of Metabolic and Anthropometric Abnormalities to Cardiovascular Disease Risk Factors
Circulation, July 8, 2008; 118(2): e20 - e28.
[Full Text] [PDF]


Home page
JAMAHome page
P. Koutkia, B. Canavan, J. Breu, M. Torriani, J. Kissko, and S. Grinspoon
Growth Hormone-Releasing Hormone in HIV-Infected Men With Lipodystrophy: A Randomized Controlled Trial
JAMA, July 14, 2004; 292(2): 210 - 218.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2003 by The Endocrine Society